{"id":"NCT04600895","sponsor":"Appili Therapeutics Inc.","briefTitle":"The Prevent Severe COVID-19 (PRESECO) Study","officialTitle":"Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-30","primaryCompletion":"2021-10-20","completion":"2021-10-20","firstPosted":"2020-10-23","resultsPosted":"2024-03-29","lastUpdate":"2024-03-29"},"enrollment":1187,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Covid19"],"interventions":[{"type":"DRUG","name":"Favipiravir","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Favipiravir","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection","primaryOutcome":{"measure":"Number of Participants With Sustained Clinical Recovery","timeFrame":"From Day 0 to Day 28","effectByArm":[{"arm":"Favipiravir","deltaMin":425,"sd":null},{"arm":"Placebo","deltaMin":475,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":23,"exclusionCount":19},"locations":{"siteCount":38,"countries":["United States","Brazil","Mexico"]},"refs":{"pmids":["36065065"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":599},"commonTop":["Nausea","Dizziness","Cough","Diarrhoea","COVID-19 pneumonia"]}}